(Q28484572)

English

Combined Inhibition of IGF-1R/IR and Src family kinases enhances antitumor effects in prostate cancer by decreasing activated survival pathways

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

0 references

Combined Inhibition of IGF-1R/IR and Src family kinases enhances antitumor effects in prostate cancer by decreasing activated survival pathways (English)

0 references

prostate cancer

1 reference

based on heuristic

inferred from title

object named as

Shhyam Moorthy

5

author given names

Shhyam

author last names

Moorthy

1 reference

PubMed publication ID

21 October 2023

author name string

Farshid Dayyani

1

author given names

Farshid

author last names

Dayyani

1 reference

PubMed publication ID

21 October 2023

Nila U Parikh

2

author given names

Nila U

author last names

Parikh

1 reference

PubMed publication ID

21 October 2023

Andreas S Varkaris

3

author given names

Andreas S

author last names

Varkaris

1 reference

PubMed publication ID

21 October 2023

Jian H Song

4

author given names

Jian H

author last names

Song

1 reference

PubMed publication ID

21 October 2023

Tanushree Chatterji

6

author given names

Tanushree

author last names

Chatterji

1 reference

PubMed publication ID

21 October 2023

Sankar N Maity

7

author given names

Sankar N

author last names

Maity

1 reference

PubMed publication ID

21 October 2023

Adam R Wolfe

8

author given names

Adam R

author last names

Wolfe

1 reference

PubMed publication ID

21 October 2023

Joan M Carboni

9

author given names

Joan M

author last names

Carboni

1 reference

PubMed publication ID

21 October 2023

Marco M Gottardis

10

author given names

Marco M

author last names

Gottardis

1 reference

PubMed publication ID

21 October 2023

Christopher J Logothetis

11

author given names

Christopher J

author last names

Logothetis

1 reference

PubMed publication ID

21 October 2023

Gary E Gallick

12

author given names

Gary E

author last names

Gallick

1 reference

PubMed publication ID

21 October 2023

language of work or name

0 references

publication date

2012

0 references

0 references

7

0 references

12

0 references

e51189

0 references

copyright license

Creative Commons Attribution 4.0 International

26 December 2012

1 reference

April 2022 Public Data File from Crossref

copyright status

0 references

Cancer statistics, 2012

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3530555

19 March 2017

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3530555

19 March 2017

AFAP-110 is overexpressed in prostate cancer and contributes to tumorigenic growth by regulating focal contacts

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3530555

19 March 2017

Increased insulin-like growth factor I receptor expression and signaling are components of androgen-independent progression in a lineage-derived prostate cancer progression model

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3530555

19 March 2017

Src family kinases in tumor progression and metastasis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3530555

19 March 2017

Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3530555

7 April 2017

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3530555

7 April 2017

Abiraterone and increased survival in metastatic prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3530555

7 April 2017

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3530555

7 April 2017

Drug combination studies and their synergy quantification using the Chou-Talalay method

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3530555

7 April 2017

Acquired resistance to tamoxifen is associated with loss of the type I insulin-like growth factor receptor: implications for breast cancer treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3530555

29 September 2017

The receptor tyrosine kinase Axl is an essential regulator of prostate cancer proliferation and tumor growth and represents a new therapeutic target.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3530555

29 September 2017

The role of HGF/c-Met signaling in prostate cancer progression and c-Met inhibitors in clinical trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3530555

29 September 2017

Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3530555

29 September 2017

Novel therapies for metastatic castrate-resistant prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3530555

29 September 2017

Targeting the insulin-like growth factor signaling pathway: figitumumab and other novel anticancer strategies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3530555

29 September 2017

BMP4 promotes prostate tumor growth in bone through osteogenesis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3530555

29 September 2017

Pre-clinical mouse models of human prostate cancer and their utility in drug discovery

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3530555

29 September 2017

PC3 is a cell line characteristic of prostatic small cell carcinoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3530555

29 September 2017

Insulin-Like Growth Factor I Suppresses Bone Morphogenetic Protein Signaling in Prostate Cancer Cells by Activating mTOR Signaling

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3530555

29 September 2017

SKI-606 (Bosutinib) blocks prostate cancer invasion, growth, and metastasis in vitro and in vivo through regulation of genes involved in cancer growth and skeletal metastasis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3530555

29 September 2017

Src family kinase/abl inhibitor dasatinib suppresses proliferation and enhances differentiation of osteoblasts.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3530555

29 September 2017

Targeting of bone-derived insulin-like growth factor-II by a human neutralizing antibody suppresses the growth of prostate cancer cells in a human bone environment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3530555

29 September 2017

BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3530555

29 September 2017

Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3530555

29 September 2017

Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3530555

29 September 2017

PIK3CA mutations in human solid tumors: role in sensitivity to various therapeutic approaches

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3530555

29 September 2017

Perifosine: update on a novel Akt inhibitor.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3530555

29 September 2017

Src as a therapeutic target in men with prostate cancer and bone metastases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3530555

29 September 2017

Rosiglitazone attenuates insulin-like growth factor 1 receptor survival signaling in PC-3 cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3530555

29 September 2017

Mechanisms of disease: signaling of the insulin-like growth factor 1 receptor pathway--therapeutic perspectives in cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3530555

29 September 2017

The role of Src in prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3530555

29 September 2017

Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3530555

29 September 2017

Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3530555

29 September 2017

Role of insulin-like growth factor 1 receptor signalling in cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3530555

29 September 2017

In vivo effects of the human type I insulin-like growth factor receptor antibody A12 on androgen-dependent and androgen-independent xenograft human prostate tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3530555

29 September 2017

Osteoblasts in prostate cancer metastasis to bone

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3530555

29 September 2017

Insulin-like growth factors and neoplasia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3530555

29 September 2017

Role of high expression levels of CXCR4 in tumor growth, vascularization, and metastasis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3530555

29 September 2017

Reduced c-Met expression by an adenovirus expressing a c-Met ribozyme inhibits tumorigenic growth and lymph node metastases of PC3-LN4 prostate tumor cells in an orthotopic nude mouse model

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3530555

29 September 2017

Autophagy Blockade Sensitizes Prostate Cancer Cells towards Src Family Kinase Inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3530555

2 June 2018

Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0051189

21 January 2018

Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0051189

21 January 2018

Insulin-Like Growth Factor I (IGF-I) and IGF Binding Protein-1 Modulate Prostate Cancer Cell Growth and Apoptosis: Possible Mediators for the Effects of Diet and Exercise on Cancer Cell Survival

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0051189

21 January 2018

Targeting platelet-derived growth factor receptor on endothelial cells of multidrug-resistant prostate cancer.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0051189

21 January 2018

Src activation regulates anoikis in human colon tumor cell lines

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0051189

21 January 2018

Dasatinib is a potent inhibitor of tumour-associated macrophages, osteoclasts and the FMS receptor.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0051189

21 January 2018

The tyrosine kinase inhibitor dasatinib dysregulates bone remodeling through inhibition of osteoclasts in vivo

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0051189

21 January 2018

An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3530555

27 November 2018

Adenoviral-mediated expression of MMAC/PTEN inhibits proliferation and metastasis of human prostate cancer cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3530555

27 November 2018

Molecular classification of human carcinomas by use of gene expression signatures.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3530555

27 November 2018

Overexpression of insulin-like growth factor binding protein-5 helps accelerate progression to androgen-independence in the human prostate LNCaP tumor model through activation of phosphatidylinositol 3'-kinase pathway

1 reference

https://pubmed.ncbi.nlm.nih.gov/23300537

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bone Growth Factors

1 reference

https://pubmed.ncbi.nlm.nih.gov/23300537

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1371/JOURNAL.PONE.0051189

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

2012PLoSO...751189D

0 references

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

PMC publication ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

PubMed publication ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q28484572&oldid=1994457256"